Findings

What do systematic reviews say?

26 questions · 26 findings · 8 reviews

No studies found 5 · 19.2%GRADE not reported 0 · 0%Very low 12 · 46.2%Low 4 · 15.4%Moderate 3 · 11.5%High 2 · 7.7%

All‐cause mortality at 1 year · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus cisplatin changes all‐cause mortality at 1 year compared with S‐1 plus cisplatin (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 0.76 [0.58, 0.98]
1 study · 96 participants
Very low

Serious adverse events · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Health‐related quality of life · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Overall response rate · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus cisplatin changes overall response rate compared with S‐1 plus cisplatin (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 0.82 [0.37, 1.82]
1 study · 88 participants
Very low

Time to progression of the tumour · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Grade 1 ‐ 4 anaemia · people with advanced biliary tract carcinomas

It is very uncertain whether gemcitabine plus cisplatin changes grade 1 ‐ 4 anaemia compared with S‐1 plus cisplatin (very low certainty).

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
RR 11.27 [4.41, 28.83]
1 study · 96 participants
Very low